Kidney cancer
BMS left red-faced as Opdivo+Yervoy fails to beat rival Pfizer drug in kidney cancer
August 16, 2017Research and Development BMS, Kidney cancer, Yervoy, life sciences, opdivo, pharma, pharmaceutical
Bristol-Myers Squibb has been left somewhat red-faced after its combination of Opdivo (nivolumab) and Yervoy (ipilimumab) failed to show any …
NICE knocks back advanced kidney cancer drug duo
August 14, 2017Sales and Marketing Cancer, Kidney cancer, NICE, medicine, pharma, pharmaceutical
NICE has dished out a double judgement turning down two drugs for advanced renal cell carcinoma, a form of kidney …
Ipsen secures NICE approval for multi-targeting kidney cancer therapy
July 11, 2017Manufacturing and Production, Sales and Marketing Cabometyx, Kidney cancer, NICE
Ipsen has announced that its therapy Cabometyx (cabozantinib) has been given approval by NICE for the treatment of advanced renal …
Pfizer says its Sutent meets primary endpoint in Phase III trials for kidney cancer recurrence
July 11, 2016Research and Development, Sales and Marketing Kidney cancer, Pfizer, Stutent, drug trial
US pharma giant Pfizer (NYSE: PFE) said late-stage trials for its Sutent (sunitinib) met its primary endpoint as a treatment …
FDA grants Eisai’s Lenvima priority review for kidney cancer
January 19, 2016Manufacturing and Production Breakthrough Therapy Designation, Eisai, FDA, Kidney cancer, Lenvima, lenvatinib, priority review, renal cell carcinoma
The FDA has accepted Eisai’s supplemental New Drug Application (sNDA) for its anti-cancer agent Lenvima for use in the treatment …
Bristol-Myers Squibb notches kidney cancer first with Opdivo
September 28, 2015Research and Development Afinitor, Bristol-Myers Squibb, Kidney cancer, advanced kidney cancer, everolimus, nivolumab, opdivo, renal cell carcinoma
Bristol-Myers Squibb has announced positive results from a Phase III study comparing Opdivo to Afinitor, the Novartis treatment that is …
FDA grants Opdivo breakthrough status for kidney cancer
September 18, 2015Research and Development, Sales and Marketing BMS, Breakthrough Therapy Designation, Bristol-Myers Squibb, FDA, Kidney cancer, immuno-oncology, immunotherapy, nivolumab, opdivo, renal cell carcinoma
The FDA has given Bristol-Myers Squibb’s immuno-oncology drug Opdivo Breakthrough Therapy Designation as a kidney cancer treatment. The FDA’s decision …
BMS halts Opdivo kidney cancer trial early
July 22, 2015Research and Development BMS, Bristol-Myers Squibb, European Commission, Kidney cancer, opdivo, renal cell carcinoma
Bristol-Myers Squibb has stopped its Phase III study of its immunotherapy drug Opdivo in people with kidney cancer early after …
NICE U-turn on Pfizer drug Inlyta
March 5, 2014Research and Development, Sales and Marketing Kidney cancer, NHS, NICE, Pfizer, axitinib, inlyta
NICE has recommended that Pfizer’s kidney cancer drug Inlyta should be used for some patients in England, following a similar …
NICE unimpressed with Novartis’ patient access scheme
April 19, 2011Sales and Marketing Afinitor, Kidney cancer, NICE, Novartis
Novartis has been dealt a blow by NICE after the cost-effectiveness body finally refused to recommend, on appeal, its kidney …
NICE yes for Votrient, no to Avastin
February 23, 2011Sales and Marketing Cancer, GSK, GlaxoSmithKline, Kidney cancer, NICE, Roche, avastin, bevacizumab, breast cancer
NICE has recommended GlaxoSmithKline’s kidney cancer drug Votrient on the same day it gave a final negative decision to Roche’s …
Astellas to commercialise new kidney cancer drug in Europe
February 21, 2011Sales and Marketing Astellas, Aveo Pharmaceuticals, Cancer, Kidney cancer, rcc, renal cell carcinoma, tivozanib
Astellas and Aveo Pharmaceuticals are to commercialise Aveo’s investigational kidney cancer drug tivozanib in Europe and the US. Aveo is …
Novartis fails to sway NICE with Afinitor deal
November 26, 2010Sales and Marketing Afinitor, Kidney cancer, NICE, Novartis, advanced renal cell carcinoma, everolimus
Novartis has failed to convince NICE that its revised patient access scheme for Afinitor would make the kidney cancer drug …
Pfizer’s axitinib impresses in head-to-head trial with Nexavar
November 22, 2010Research and Development, Sales and Marketing Kidney cancer, Nexavar, Pfizer, axitinib, mRCC, metastatic renal cell carcinoma
Pfizer’s axitinib has impressed in phase III trials assessing its efficacy as a second line treatment for renal cell carcinoma. …
GSK tipped to lead kidney cancer market
July 1, 2010Sales and Marketing Kidney cancer, Patorma, Votrient, rcc
GlaxoSmithKline’s kidney cancer drug Votrient has been forecast as a future leader in a marketplace currently dominated by Pfizer. Analysts …
Latest content
FibroFind appoints Lee Borthwick as CEO
